Literature DB >> 8207825

First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

J P Langeveld1, J I Casal, A D Osterhaus, E Cortés, R de Swart, C Vela, K Dalsgaard, W C Puijk, W M Schaaper, R H Meloen.   

Abstract

A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic properties of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with marker vaccines, it is possible to discriminate between vaccinated dogs that have not been exposed to the virus and dogs that have been infected with the virus. The protective mechanism can be explained by a humoral response against the peptide aided by T-cell epitopes contained in the carrier protein used for peptide coupling. This is the first example of a synthetic peptide vaccine that induces protection in target animals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207825      PMCID: PMC236377     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Production of porcine parvovirus empty capsids with high immunogenic activity.

Authors:  C Martínez; K Dalsgaard; J A López de Turiso; E Cortés; C Vela; J I Casal
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Isolation and characterization of the neutralizable epitope of simian retrovirus-1 (SRV-1) and of the cell receptor for the virus.

Authors:  E Benjamini; J V Torres; L L Werner; A Malley
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

4.  Candidate recombinant vaccine for human B19 parvovirus.

Authors:  G P Bansal; J A Hatfield; F E Dunn; A A Kramer; F Brady; C H Riggin; M S Collett; K Yoshimoto; S Kajigaya; N S Young
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

5.  Recombinant vaccine for canine parvovirus in dogs.

Authors:  J A López de Turiso; E Cortés; C Martínez; R Ruiz de Ybáñez; I Simarro; C Vela; I Casal
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface.

Authors:  J P Langeveld; J I Casal; C Vela; K Dalsgaard; S H Smale; W C Puijk; R H Meloen
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

7.  The trypsin-sensitive RVER domain in the capsid proteins of minute virus of mice is required for efficient cell binding and viral infection but not for proteolytic processing in vivo.

Authors:  G E Tullis; L R Burger; D J Pintel
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

8.  HBTU activation for automated Fmoc solid-phase peptide synthesis.

Authors:  C G Fields; D H Lloyd; R L Macdonald; K M Otteson; R L Noble
Journal:  Pept Res       Date:  1991 Mar-Apr

9.  Structure, sequence, and function correlations among parvoviruses.

Authors:  M S Chapman; M G Rossmann
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

10.  Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody.

Authors:  T Trirawatanapong; B Chandran; R Putnak; R Padmanabhan
Journal:  Gene       Date:  1992-07-15       Impact factor: 3.688

View more
  25 in total

1.  Benchmarking B cell epitope prediction: underperformance of existing methods.

Authors:  Martin J Blythe; Darren R Flower
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

2.  Mapping Antigenic Epitopes on the Human Bocavirus Capsid.

Authors:  Shweta Kailasan; Jamie Garrison; Maria Ilyas; Paul Chipman; Robert McKenna; Kalle Kantola; Maria Söderlund-Venermo; Indrė Kučinskaitė-Kodzė; Aurelija Žvirblienė; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 3.  Designing therapeutic cancer vaccines by mimicking viral infections.

Authors:  Hussein Sultan; Valentyna I Fesenkova; Diane Addis; Aaron E Fan; Takumi Kumai; Juan Wu; Andres M Salazar; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2016-04-06       Impact factor: 6.968

4.  Identification of new tag sequences with differential and selective recognition properties for the anti-FLAG monoclonal antibodies M1, M2 and M5.

Authors:  J W Slootstra; D Kuperus; A Plückthun; R H Meloen
Journal:  Mol Divers       Date:  1997       Impact factor: 2.943

5.  Peptide vaccine against canine parvovirus: identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence.

Authors:  J I Casal; J P Langeveld; E Cortés; W W Schaaper; E van Dijk; C Vela; S Kamstrup; R H Meloen
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Identification of domains in canine parvovirus VP2 essential for the assembly of virus-like particles.

Authors:  A Hurtado; P Rueda; J Nowicky; J Sarraseca; J I Casal
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Predicting peptide vaccine candidates against H1N1 influenza virus through theoretical approaches.

Authors:  Martiniano Bello; Rafael Campos-Rodriguez; Saul Rojas-Hernandez; Arturo Contis-Montes de Oca; José Correa-Basurto
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

8.  Canine parvovirus type 2c in Vietnam continues to produce distinct descendants with new mutations restricted to Vietnamese variants.

Authors:  Huong Thi Thanh Doan; Xuyen Thi Kim Le; Roan Thi Do; Khue Thi Nguyen; Thanh Hoa Le
Journal:  Arch Virol       Date:  2021-04-16       Impact factor: 2.574

Review 9.  Cowpea mosaic virus as a vaccine carrier of heterologous antigens.

Authors:  F R Brennan; T D Jones; W D Hamilton
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

Review 10.  Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality.

Authors:  S Chebolu; H Daniell
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.